In:
Advanced Healthcare Materials, Wiley, Vol. 8, No. 11 ( 2019-06)
Abstract:
Extracellular vesicles (EVs) are promising natural nanocarriers for delivery of various types of therapeutics. Earlier engineered EV‐based formulations for neurodegenerative diseases and cancer are reported. Herein, the use of macrophage‐derived EVs for brain delivery of a soluble lysosomal enzyme tripeptidyl peptidase‐1, TPP1, to treat a lysosomal storage disorder, Neuronal Ceroid Lipofuscinoses 2 (CLN2) or Batten disease, is investigated. TPP1 is loaded into EVs using two methods: i) transfection of parental EV‐producing macrophages with TPP1‐encoding plasmid DNA ( p DNA) or ii) incorporation therapeutic protein TPP1 into naive empty EVs. For the former approach, EVs released by pretransfected macrophages contain the active enzyme and TPP1‐encoding p DNA. To achieve high loading efficiency by the latter approach, sonication or permeabilization of EV membranes with saponin is utilized. Both methods provide proficient incorporation of functional TPP1 into EVs (EV‐TPP1). EVs significantly increase stability of TPP1 against protease degradation and provide efficient TPP1 delivery to target cells in in vitro model of CLN2. The majority of EV‐TPP1 (≈70%) is delivered to target organelles, lysosomes. Finally, a robust brain accumulation of EV carriers and increased lifespan is recorded in late‐infantile neuronal ceroid lipofuscinosis (LINCL) mouse model following intraperitoneal administration of EV‐TPP1.
Type of Medium:
Online Resource
ISSN:
2192-2640
,
2192-2659
DOI:
10.1002/adhm.201801271
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
2645585-7
detail.hit.zdb_id:
2649576-4
Permalink